There are so many biotechs over the past couple of years that have released Phase 2 data and have had their stocks go up 10, 20, 50, 100%. Take ARQL in one instance.
Which I why I say it will surprise me if there is no reaction (unless Merck says it didn't meet their criteria to continue ..which I doubt they would)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.